Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation 68% reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4 Resolution of suicidal ideation achieved by 60% of patients by Week 1, and 78% by Week 4 Effects consistent with...

Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder Rapid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months Rapid and substantial improvement in...

ThalesNano entered into the international flow chemistry consortium “Center for Continuous Flow Synthesis & Processing” – (CC Flow) BUDAPEST, Hungary, May 10, 2018 (GLOBE NEWSWIRE) -- With recent advances in continuous flow chemistry synthesis and processing the “Center for Continuous Flow Synthesis & Processing” consortium...